EUVIMEDEUVIMED entdecken
Open Access

A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years — China, 2021–2023

Jingyu Li, Yu Zhao, Yan Zheng, Xuexia Zhang, Ya Jiang, Jiangshu Guo, Wenmei Bao, Yinfeng Ma, Yaoyuan Zhang, Shuyuan Yin, Yirui Ma, Lijie Wang und 1 weitere

China CDC Weekly · 2026 · 8 (17) · 513-519

DOI: 10.46234/ccdcw2026.083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift China CDC Weekly, 2026. Verfasst von Jingyu Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan Province, China. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Ormutivimabanti-rabies virus monoclonal antibodyrabiesrabies virus

Autor:innen und Institutionen

  • Yunnan Provincial Center for Disease Control and Prevention, Kunming City, Yunnan Province, China.
  • State Key Laboratory of Antibody Research and Development, North China Pharmaceutical Company (NCPC) New Drug Research and Development Co., Ltd., Shijiazhuang City, Hebei Province, China.
  • Mile Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture, Yunnan Province, China.
  • Gejiu Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture, Yunnan Province, China.
  • Kaiyuan Center for Disease Control and Prevention, Honghe Hani and Yi Autonomous Prefecture, Yunnan Province, China.
  • Qiubei County Center for Disease Control and Prevention, Wenshan Zhuang and Miao Autonomous Prefecture, Yunnan Province, China.

Zitieren

APA

Li, J., Zhao, Y., Zheng, Y., Zhang, X., Jiang, Y., Guo, J., Bao, W., Ma, Y., Zhang, Y., Yin, S., Ma, Y., Wang, L., & Liu, X. (2026). A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years — China, 2021–2023. China CDC Weekly, 8(17), 513-519. https://doi.org/10.46234/ccdcw2026.083

Vancouver

Li J, Zhao Y, Zheng Y, Zhang X, Jiang Y, Guo J, et al. A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years — China, 2021–2023. China CDC Weekly. 2026;8(17):513-519. doi:10.46234/ccdcw2026.083

BibTeX
@article{Li2026,
  author = {Li, Jingyu and Zhao, Yu and Zheng, Yan and Zhang, Xuexia and Jiang, Ya and Guo, Jiangshu and Bao, Wenmei and Ma, Yinfeng and Zhang, Yaoyuan and Yin, Shuyuan and Ma, Yirui and Wang, Lijie and Liu, Xiaoqiang},
  title = {A Randomized, Double-Blind, Positive-Controlled Phase III Clinical Trial of an Anti-Rabies Monoclonal Antibody for Category III Rabies Exposure in Individuals Under 18 Years — China, 2021–2023},
  journal = {China CDC Weekly},
  year = {2026},
  volume = {8},
  number = {17},
  pages = {513--519},
  doi = {10.46234/ccdcw2026.083}
}
Kostenlos starten →